Merck posts quarterly loss due to Cidara charge, sales rise 5%

Merck reported Q1 revenue of $16.3 billion, ahead of the $15.8 billion consensus, while adjusted loss per share of $1.28 was better than the $1.51 loss expected despite a $3.62 per share acquisition-related charge. Keytruda sales rose 12% to $8.0 billion, Winrevair jumped 88% to $525 million, and full-year 2026 guidance was narrowed and nudged higher to $5.04-$5.16 EPS on $65.8 billion-$67.0 billion in sales. Offsets included a 28% drop in Januvia sales and a 19% decline in Gardasil sales.

Analysis

This is less a clean beat than a proof that Merck can still compound through the patent cliff by shifting the growth engine toward newer oncology/respiratory assets. The key second-order read-through is that a stronger long-duration revenue base gives management more flexibility to keep doing deal-driven augmentation without immediately forcing a multiple reset, which matters for how the market should handicap future M&A. In other words, the earnings quality is improving even if reported EPS is being obscured by acquisition accounting.

For competitors, the most important implication is that Merck is getting better at defending share in the immuno-oncology franchise while layering in adjacent launches, which raises the bar for other large-cap pharma to show organic growth rather than rely on balance-sheet maneuvers. That tends to pressure slower growers with similar “single-asset dependence” profiles, because investors will be less willing to pay up for names that lack a visible post-patent-cliff bridge. The cleanest beneficiary set is not the obvious suppliers, but biotech targets with differentiated assets that now look strategically more valuable as big pharma’s bar for bolt-on acquisitions rises.

The main risk is that the market may over-focus on the headline guidance raise and underweight the fact that a meaningful part of the near-term EPS bridge is still being normalized away by one-time charges. Over the next 1-3 months, sentiment can remain positive if the launch momentum persists, but over 6-12 months the real test is whether growth broadens beyond the current concentrated set of winners and whether declines in legacy products accelerate faster than expected. Any stumble in execution on new formulations or payer pushback would quickly re-open the narrative that the company is just buying time.

Contrarian take: the move may be underappreciated if investors are still valuing Merck as a mature ex-growth large-cap pharma rather than a self-funded growth platform with optionality from M&A. The market is likely still discounting the durability of newer franchises versus the decay in older brands, which creates a setup where the stock can rerate on evidence of sustained mid-single-digit top-line growth. The better trade is to own the cleaner growth-plus-capital-deployment story rather than chase the legacy-drug name with the most visible cliff.

Key Decisions for Investors

• Long MRK on a 3-6 month horizon; thesis is that recurring growth plus acquisitive optionality supports a modest multiple rerate. Risk/reward is favorable if the market starts capitalizing the new product mix instead of the one-time charges.
• Pair trade: long MRK / short a slower-growth large-cap pharma with heavier legacy-product exposure over 3-6 months. The relative trade benefits if investors reward visible post-cliff growth and punish names without a comparable pipeline bridge.
• Buy MRK call spreads for the next 2-4 months if implied volatility is reasonable; use upside participation tied to continued launch momentum while capping premium outlay. Best suited for a catalyst-driven rerating rather than a fundamental long-only add.
• Watch TERN as a short-duration event-driven name only after deal mechanics are fully digested; avoid chasing the headline until the market prices the one-time charge versus strategic value. Risk/reward is asymmetric if deal completion risk or dilution concerns resurface.